Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Structures from WO 2005/041904. (a–e) exemplified structures with the most potent K i s against SARS‐CoV 3CL pro .

Article Snippet: The second earliest patent application on SARS‐CoV 3CL pro inhibitors was filed by Cytovia in 2004 (WO 2004/101742; Table ) describing 2‐residue peptidomimetics containing a P1 glutamine residue with a C‐terminal electrophilic monofluoromethylketone warhead (Figure ).

Techniques:

Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Six most potent SARS‐CoV 3CL pro inhibitors reported in US 2006/0019967.

Article Snippet: The second earliest patent application on SARS‐CoV 3CL pro inhibitors was filed by Cytovia in 2004 (WO 2004/101742; Table ) describing 2‐residue peptidomimetics containing a P1 glutamine residue with a C‐terminal electrophilic monofluoromethylketone warhead (Figure ).

Techniques:

Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Structures from WO 2017/114509. (a) general scaffold; (b–f) most potent exemplified inhibitors against SARS‐CoV 3CL pro .

Article Snippet: The second earliest patent application on SARS‐CoV 3CL pro inhibitors was filed by Cytovia in 2004 (WO 2004/101742; Table ) describing 2‐residue peptidomimetics containing a P1 glutamine residue with a C‐terminal electrophilic monofluoromethylketone warhead (Figure ).

Techniques:

Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Structures from WO 2020/030143. (a) general scaffold; (b–f) most potent exemplified MERS‐CoV 3CL pro inhibitors.

Article Snippet: The second earliest patent application on SARS‐CoV 3CL pro inhibitors was filed by Cytovia in 2004 (WO 2004/101742; Table ) describing 2‐residue peptidomimetics containing a P1 glutamine residue with a C‐terminal electrophilic monofluoromethylketone warhead (Figure ).

Techniques:

Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Summary of SARS coronavirus 3CL pro inhibitor patents in chronological order up to 30 July 2021.

Article Snippet: The third earliest patent on coronavirus 3CL pro inhibitors was filed in 2004 by Agouron Pharmaceuticals involving 1‐, 2‐ and 3‐residue peptidomimetics bearing a P1 5‐membered lactam glutamine mimic with a C‐terminal electrophilic α,β‐unsaturated ester warhead (US 2006/0014821; Table ).

Techniques:

Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Structures from WO 2005/041904. (a–e) exemplified structures with the most potent K i s against SARS‐CoV 3CL pro .

Article Snippet: The third earliest patent on coronavirus 3CL pro inhibitors was filed in 2004 by Agouron Pharmaceuticals involving 1‐, 2‐ and 3‐residue peptidomimetics bearing a P1 5‐membered lactam glutamine mimic with a C‐terminal electrophilic α,β‐unsaturated ester warhead (US 2006/0014821; Table ).

Techniques:

Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Six most potent SARS‐CoV 3CL pro inhibitors reported in US 2006/0019967.

Article Snippet: The third earliest patent on coronavirus 3CL pro inhibitors was filed in 2004 by Agouron Pharmaceuticals involving 1‐, 2‐ and 3‐residue peptidomimetics bearing a P1 5‐membered lactam glutamine mimic with a C‐terminal electrophilic α,β‐unsaturated ester warhead (US 2006/0014821; Table ).

Techniques:

Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Structures from WO 2017/114509. (a) general scaffold; (b–f) most potent exemplified inhibitors against SARS‐CoV 3CL pro .

Article Snippet: The third earliest patent on coronavirus 3CL pro inhibitors was filed in 2004 by Agouron Pharmaceuticals involving 1‐, 2‐ and 3‐residue peptidomimetics bearing a P1 5‐membered lactam glutamine mimic with a C‐terminal electrophilic α,β‐unsaturated ester warhead (US 2006/0014821; Table ).

Techniques:

Journal: Chemmedchem

Article Title: A Patent Review on SARS Coronavirus Main Protease (3CL pro ) Inhibitors

doi: 10.1002/cmdc.202100576

Figure Lengend Snippet: Structures from WO 2020/030143. (a) general scaffold; (b–f) most potent exemplified MERS‐CoV 3CL pro inhibitors.

Article Snippet: The third earliest patent on coronavirus 3CL pro inhibitors was filed in 2004 by Agouron Pharmaceuticals involving 1‐, 2‐ and 3‐residue peptidomimetics bearing a P1 5‐membered lactam glutamine mimic with a C‐terminal electrophilic α,β‐unsaturated ester warhead (US 2006/0014821; Table ).

Techniques: